Double the dose from an identical syringe reading
The brand premium covers Novo Nordisks marketing, patent protection, and distribution infrastructure not a better version of the drug
Despite the runaway commercial success of injectables semaglutide and tirzepatide, and a projected global opportunity for obesity pharmacotherapies worth $131Bn by 2028 [2], a number of important issues must be addressed for anti-obesity medicines to fulfil their tremendous potential as public health interventions: Ensuring affordability by patients, in out-of-pocket markets, and by health systems to expand reimbursement of weight loss medicines to ensure equity of access and enable the broad adoption of therapies in eligible patient populations Securing adequate product supply that meets fast growing demand Maintaining weight loss and realising associated, long-term health benefits, e.g., improvements in cardio-metabolic risk factors and co-morbidities Oral obesity treatments will play a critical role in overcoming these challenges, for example, as convenient, long-term maintenance therapy following time-limited induction therapy with injectables
Gradually reintroduce fiber as tolerance improves, starting with soluble fiber sources like oats and ripe bananas
After submission, a licensed provider reviews your information and may adjust or recommend a different medication, route, or protocol if clinically appropriate
Another paper found that people with a genetic tendency toward low dopamine levels may face higher risk of depression and suicidal thoughts on these medications
